Prognostic impact of KRAS mutation in cell-free DNA in patients with pancreatic cancer

Kim, M.K.; Woo, Sang Myung; Park, B.; Yoon, K S; Kim, Y.H.; Joo, Jungnam; Park, S.J.; Kong, S-Y

doi:10.1093/annonc/mdx361.029

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…cfDNA testing can identify 62% of mutations (alterations), and 30% of them are different from those detected in tissues. Interestingly, a concordance rate of >75% has been found in studies of mut- KRAS alone [ 33 , 34 ]. Therefore, cfDNA testing can serve as an alternative in PDA patients.…”

Section: Detection Of Cfdna In Pdamentioning

confidence: 99%

“…The absence of detectable mutations ( KRAS negativity) after either surgical or pharmacological treatment in patients with prior mut- KRAS detection has been found to indicate favorable prognosis (HR = 2.46, 95% CI: 2.01–3.00). Additionally, researchers have empirically demonstrated that, when combined with CA19-9, the detection and concentration of mut- KRAS in cfDNA have greater prognostic value than those of CA19-9 alone across all stages (HR = 2.08; 95% CI: 1.20–3.63) [ 33 ].…”

Section: Prognostic Value Of Cfdna In Pdamentioning

confidence: 99%

See 1 more Smart Citation

Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time?

Sheel

Addison

Nuguru

et al. 2022

Cancers

View full text Add to dashboard Cite

Cell-free DNA (cfDNA) testing currently does not have a significant role in PDA management: it is insufficient to diagnose PDA, and its use is primarily restricted to identifying targetable mutations (if tissue is insufficient or unavailable). cfDNA testing has the potential to address critical needs in PDA management, such as pre-operative risk stratification (POR), prognostication, and predicting (and monitoring) treatment response. Prior studies have focused primarily on somatic mutations, specifically KRAS variants, and have shown limited success in addressing prognosis and POR. Recent studies have demonstrated the importance of other less prevalent mutations (ERBB2 and TP53), but no studies have provided reliable mutation panels for clinical use. Methylation aberrations in cfDNA (epigenetic markers) in PDA have been relatively less explored. However, early evidence has suggested they offer diagnostic and, to some extent, prognostic value. The inclusion of epigenetic markers of cfDNA adds another dimension to genomic testing and may open new therapeutic avenues beyond addressing critical areas of need in PDA treatment. For cfDNA to substantially influence PDA management, concerted efforts are required to include less frequent mutations and epigenetic markers. Furthermore, relying on KRAS mutations for PDA management will always be inadequate.

show abstract

Section: Detection Of Cfdna In Pdamentioning

confidence: 99%

Section: Prognostic Value Of Cfdna In Pdamentioning

confidence: 99%